September 28, 2005 -- The FDA rejected a generic pain patch from Noven, sending the stock 16% lower, the FDA also asked Incyte to put its HIV drug through another Phase II trial, putting the stock in a 41% decline, Insmed received an approvable letter from the FDA for a growth failure treatment, cancer drug Revlimid from Celgene was suspended because of blood clot problems, Cytokinetics will continue a breast cancer test but stop a trial in lung cancer, GlaxoSmithKline warned that its antidepressant, Paxil, may cause birth defects, Altus reported positive data from its once-weekly drug for growth hormone deficiency, and Boston Scientific has stopped sales of Enteryx, a treatment for acid reflux disease. The Centient Biotech 200™ rose 22 points to 3732.58, a gain of .59%. More details...
